Similar articles

• Oblimersen in the treatment of metastatic melanoma.

  Tarhini AA, Kirkwood JM. Tarhini AA, et al. Future Oncol. 2007 Jun;3(3):263-71. doi: 10.2217/14796694.3.3.263. Future Oncol. 2007. PMID: 17547520 Review.
• Apoptosis, Bcl-2 antisense, and cancer therapy.

  Piro LD. Piro LD. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):5-10. Oncology (Williston Park). 2004. PMID: 15651171 Review.
• Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

  Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bedikian AY, et al. J Clin Oncol. 2006 Oct 10;24(29):4738-45. doi: 10.1200/JCO.2006.06.0483. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966688 Clinical Trial.
• Genta initiates trials with Genasense.

  [No authors listed] [No authors listed] Expert Rev Anticancer Ther. 2002 Feb;2(1):6. Expert Rev Anticancer Ther. 2002. PMID: 12113068 No abstract available.
• [At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].

  Bénard J. Bénard J. Bull Cancer. 1998 Jun;85(6):520-1. Bull Cancer. 1998. PMID: 9752277 French. No abstract available.